ATXN7L3B

ATXN7L3B is a cytoplasmic protein that acts as a dominant-negative regulator of the SAGA deubiquitinase (DUB) module by sequestering the shared co-factor ENY2 away from the nucleus (PMID:27601583). It binds ENY2 but none of the other SAGA components, and in vitro it competes directly with ATXN7L3 for ENY2; a reconstituted USP22-ATXN7L3B-ENY2 complex is catalytically deficient and cannot efficiently deubiquitinate H2Bub1, unlike the ATXN7L3-containing module (PMID:27601583). Consistent with this antagonism, overexpression of ATXN7L3B raises global H2Bub1 levels while its knockdown destabilizes ENY2 (PMID:27601583). Through this regulatory role ATXN7L3B influences estrogen receptor target gene expression and breast cancer cell migration (PMID:27601583) and promotes hepatocellular carcinoma stemness, an activity reduced by metformin (PMID:34375763). Its upregulation also drives osteogenic differentiation of adipose-derived stem cells (PMID:41245170), and a synonymous promoter-proximal SNP (rs590352) modulates its allele-asymmetric expression by disrupting transcription factor binding (PMID:41217722).

1. 2014 Low

   Before the protein was characterized, the question was whether the ATXN7L3B locus had any regulatory output; the lncRNA product lnc-SCA7 was found to engage in post-transcriptional cross-talk with ATXN7 mRNA via miR-124, establishing the locus as part of a SCA7-relevant regulatory loop.

   Evidence RNA interaction studies, miRNA reporter assays, and SCA7 mouse models

   PMID:25306109

   Open questions at the time

   • This finding concerns the lncRNA product of the locus, not the ATXN7L3B protein
   • Does not address ATXN7L3B protein function or its relationship to SAGA
   • Mechanistic link between the lncRNA loop and protein-level activity is unestablished
2. 2016 High

   The central question of what ATXN7L3B does at the molecular level was answered by showing it binds ENY2 (but no other SAGA subunit), localizes to the cytoplasm, and competes with ATXN7L3 for ENY2 to form a catalytically dead DUB module that fails to remove H2Bub1.

   Evidence Co-IP, subcellular fractionation, in vitro competition binding, and reconstituted in vitro deubiquitinase assays with USP22/ATXN7L3/ENY2

   PMID:27601583

   Open questions at the time

   • Structural basis of ATXN7L3B-ENY2 binding and how it excludes USP22 activity is not resolved
   • Whether ENY2 sequestration occurs constitutively or is regulated by signaling is unknown
   • No cell-type-resolved measurement of the in vivo ATXN7L3B:ATXN7L3 ratio governing H2Bub1
3. 2016 Medium

   Cellular gain- and loss-of-function established that ATXN7L3B antagonism of SAGA DUB activity has functional consequences, raising global H2Bub1 and supporting ER target gene expression and breast cancer cell migration.

   Evidence Overexpression/knockdown with H2Bub1 and ENY2 western blots; siRNA knockdown with migration assays and ER target gene expression analysis

   PMID:27601583

   Open questions at the time

   • Direct demonstration that migration and ER gene effects require H2Bub1/ENY2 sequestration (vs an independent activity) is incomplete
   • Single method per phenotypic readout
   • No genome-wide map of H2Bub1 changes driven by ATXN7L3B
4. 2021 Medium

   Extending its oncogenic relevance, ATXN7L3B was shown to promote hepatocellular carcinoma tumor-initiating capacity and to be a metformin-responsive target, linking it to cancer stemness.

   Evidence Transcriptomic/proteomic profiling, knockdown/overexpression with tumor-initiating assays, and an in vivo HCC mouse model with metformin treatment

   PMID:34375763

   Open questions at the time

   • Whether HCC stemness depends on the ENY2/H2Bub1 axis or a separate mechanism is unresolved
   • How metformin lowers ATXN7L3B levels is not defined
   • Limited mechanistic pathway placement
5. 2025 Medium

   The regulation and broader physiological role of ATXN7L3B were probed, showing a synonymous SNP controls its allele-specific expression via transcription factor binding, and that its upregulation drives osteogenic differentiation.

   Evidence EMSA, dual luciferase reporter, and allele-asymmetric RNA-seq for rs590352; genome-wide CRISPRa screen with alkaline phosphatase and mineralization assays in adipose-derived stem cells

   PMID:41217722 PMID:41245170

   Open questions at the time

   • The transcription factors bound at rs590352 are not identified
   • Whether the osteogenic effect operates through ENY2/H2Bub1 regulation is unknown
   • Single-study, single-lab findings for each phenotype

• It remains unresolved how the cytoplasmic ATXN7L3B-ENY2 sequestration mechanism is wired to its diverse downstream phenotypes (ER signaling, HCC stemness, osteogenesis) and whether these all converge on global H2Bub1 control.
• No structural model of the ATXN7L3B-ENY2 interface
• No causal chain linking H2Bub1 changes to specific differentiation or cancer outcomes
• Regulatory inputs controlling ATXN7L3B abundance are largely uncharacterized